Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer

References

• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67:1883-6; PMID:17332313; http://dx.doi.org/10.1158/0008-5472.CAN-06-4806
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Papamichail M, Perez SA. Immune classification of colorectal cancer patients: impressive but how complete? Expert Opin Biol Ther 2013; 13:517-26; PMID:23289642; http://dx.doi.org/10.1517/14712598.2013.751971
   PubMed Web of Science ®Google Scholar
• Ernst M, Ramsay RG. Colorectal cancer mouse models: Integrating inflammation and the stroma. J Gastroenterol Hepatol 2012; 27:39-50; PMID:22188027; http://dx.doi.org/10.1111/j.1440-1746.2011.06883.x
   PubMed Web of Science ®Google Scholar
• Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Eng J Med 2000; 342:69-77; PMID:10631274; http://dx.doi.org/10.1056/NEJM200001133420201
   PubMed Web of Science ®Google Scholar
• Lal N, Beggs AD, Willcox BE, Middleton GW. An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. Onco Immunol 2015; 4:e976052; PMID:25949894; http://dx.doi.org/10.4161/2162402X.2014.976052
   PubMedGoogle Scholar
• Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, Walsh MD, Simms LA, Biden KG, Young JP, Leggett BA, Jass JR, Radford-Smith GL. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001; 48:360-6; PMID:11171826; http://dx.doi.org/10.1136/gut.48.3.360
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Eng J Med 2015; 372:2509-20; PMID:26028255; http://dx.doi.org/10.1056/NEJMoa1500596
   PubMed Web of Science ®Google Scholar
• Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 2001; 158:1289-99; PMID:11290547; http://dx.doi.org/10.1016/S0002-9440(10)64080-1
   PubMed Web of Science ®Google Scholar
• Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nature Rev Cancer 2008; 8:523-34; PMID:18574464; http://dx.doi.org/10.1038/nrc2439
   PubMed Web of Science ®Google Scholar
• Ramsay RG, Ciznadija D, Mantamadiotis T, Anderson R, Pearson R. Expression of stress response protein glucose regulated protein-78 mediated by c-Myb. Int J Biochem Cell Biol 2005; 37:1254-68; PMID:15778089; http://dx.doi.org/10.1016/j.biocel.2004.12.011
   PubMed Web of Science ®Google Scholar
• Kleizen B, Braakman I. Protein folding and quality control in the endoplasmic reticulum. Curr Opin Cell Biol 2004; 16:343-9; PMID:15261665; http://dx.doi.org/10.1016/j.ceb.2004.06.012
   PubMed Web of Science ®Google Scholar
• Li Z, Li Z. Glucose regulated protein 78: a critical link between tumor microenvironment and cancer hallmarks. Biochim Biophys Acta 2012; 1826:13-22; PMID:22426159; http://dx.doi.org/10.1016/j.bbcan.2012.02.001
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao XR, Wang P, Li L, Dai Y, Huang H, Lei P, Zhu HF, Shen GX. Glucose regulated proteins 78 protects insulinoma cells (NIT-1) from death induced by streptozotocin, cytokines or cytotoxic T lymphocytes. Int J Biochem Cell Biol 2007; 39:2076-82; PMID:17689130; http://dx.doi.org/10.1016/j.biocel.2007.05.022
   PubMed Web of Science ®Google Scholar
• Jamora C, Dennert G, Lee AS. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci U S A 1996; 93:7690-4; PMID:8755537; http://dx.doi.org/10.1073/pnas.93.15.7690
   PubMed Web of Science ®Google Scholar
• Sugawara S, Takeda K, Lee A, Dennert G. Suppression of stress protein GRP78 induction in tumor B/C10ME eliminates resistance to cell mediated cytotoxicity. Cancer Res 1993; 53:6001-5; PMID:8261413
   PubMed Web of Science ®Google Scholar
• Sato M, Yao VJ, Arap W, Pasqualini R. GRP78 signaling hub a receptor for targeted tumor therapy. Adv Genet 2010; 69:97-114; PMID:20807604; http://dx.doi.org/10.1016/S0065-2660(10)69006-2
   PubMed Web of Science ®Google Scholar
• Miao RY, Drabsch Y, Cross RS, Cheasley D, Carpinteri S, Pereira L, Malaterre J, Gonda TJ, Anderson RL, Ramsay RG. MYB is essential for mammary tumorigenesis. Cancer Res 2011; 71:7029-37; PMID:21948968; http://dx.doi.org/10.1158/0008-5472.CAN-11-1015
   PubMed Web of Science ®Google Scholar
• Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001; 98:10356-61; PMID:11526241; http://dx.doi.org/10.1073/pnas.171610498
   PubMed Web of Science ®Google Scholar
• Corbett TH, Griswold DP, Jr, Roberts BJ, Peckham JC, Schabel FM, Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975; 35:2434-9; PMID:1149045
   PubMed Web of Science ®Google Scholar
• Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005; 17:133-44; PMID:15611321; http://dx.doi.org/10.1093/intimm/dxh194
   PubMed Web of Science ®Google Scholar
• Cross RS, Malaterre J, Davenport AJ, Carpinteri S, Anderson RL, Darcy PK, Ramsay RG. Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clin Translational Immunol 2015 4, e30; PMID:25671128; http://dx.doi.org/10.1038/cti.2014.29
   PubMedGoogle Scholar
• Mahadevan NR, Rodvold JJ, Zanetti M. A Janus-faced role of the unfolded protein response in antitumor immunity. Oncoimmunol 2013; 2:e23901; PMID:23762789; http://dx.doi.org/10.4161/onci.23901
   PubMedGoogle Scholar
• Zanetti M, Rodvold JJ, Mahadevan NR. The evolving paradigm of cell-nonautonomous UPR-based regulation of immunity by cancer cells. Oncogene 2016; 35:269-78; PMID:25893303; http://dx.doi.org/10.1038/onc.2015.108
   PubMed Web of Science ®Google Scholar
• Panayi GS, Corrigall VM. BiP, an anti-inflammatory ER protein, is a potential new therapy for the treatment of rheumatoid arthritis. Novartis Found Symp 2008; 291:212-6; discussion 6–24; PMID:18575276; http://dx.doi.org/10.1002/9780470754030.ch16
   PubMedGoogle Scholar
• Corrigall VM, Vittecoq O, Panayi GS. Binding immunoglobulin protein-treated peripheral blood monocyte-derived dendritic cells are refractory to maturation and induce regulatory T-cell development. Immunol 2009; 128:218-26; PMID:19740378; http://dx.doi.org/10.1111/j.1365-2567.2009.03103.x
   PubMed Web of Science ®Google Scholar
• Gonda TJ, Ramsay RG. Directly targeting transcriptional dysregulation in cancer. Nature Rev Cancer 2015; 15:686-94; PMID:26493648; http://dx.doi.org/10.1038/nrc4018
   PubMed Web of Science ®Google Scholar
• Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2013; 32:805-18; PMID:22508478; http://dx.doi.org/10.1038/onc.2012.130
   PubMed Web of Science ®Google Scholar
• Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, Hayakawa Y, Tsuruo T, Shin-ya K. Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 2004; 96:1300-10; PMID:15339968; http://dx.doi.org/10.1093/jnci/djh243
   PubMed Web of Science ®Google Scholar
• Miao YR, Eckhardt BL, Cao Y, Pasqualini R, Argani P, Arap W, Ramsay RG, Anderson RL. Inhibition of established micrometastases by targeted drug delivery via cell surface-associated GRP78. Clin Cancer Res 2013; 19:2107-16; PMID:23470966; http://dx.doi.org/10.1158/1078-0432.CCR-12-2991
   PubMed Web of Science ®Google Scholar
• Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A et al. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunol Immunother 2008; 57:1635-45; PMID:18386000; http://dx.doi.org/10.1007/s00262-008-0497-2
   PubMed Web of Science ®Google Scholar
• Carpinteri S, Williams BB, Miao Yu R, Cullinane C, Malaterre J, Norris MD, Haber M, Anderson RL, Darcy PK, Ramsay RG. Optimizing DNA Vaccines Against Nuclear Oncogenes. Immuno-Gastroenterol 2012; 1:108-18; http://dx.doi.org/10.7178/ig.19
   Google Scholar
• Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, Barten M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35:808-16; PMID:15257543; http://dx.doi.org/10.1016/j.humpath.2004.01.022
   PubMed Web of Science ®Google Scholar
• Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res 2014; 74:3238-47; PMID:24755471; http://dx.doi.org/10.1158/0008-5472.CAN-14-0013
   PubMed Web of Science ®Google Scholar
• John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 2012; 72:1651-60; PMID:22315352; http://dx.doi.org/10.1158/0008-5472.CAN-11-2788
   PubMed Web of Science ®Google Scholar